Prescribers Should Restrict the Use of Non-FDA-Approved Compounded Bioidentical Hormones, Except for Specific Medical Circumstances

The use of compounded bioidentical hormone therapies (cBHTs) — an more and more well-liked approach to decrease signs or symptoms of menopause and male hypogonadism — should be confined to the smaller quantity of clients who simply cannot benefit from an Food and drug administration-authorised hormone remedy merchandise, states a new report from the Countrywide Academies of Sciences, Engineering, and Medication.